Human IgG1 Fc protein

The in vivo grade recombinant human IgG1 Fc protein (hIgG1 Fc, Glu 99 - Lys 330 of the constant region of the IgG1 heavy chain, Accession # P01857-1) was produced in mammalian cells and purified by protein A. The hIgG1 Fc protein includes the CH2 (111-223) and CH3 (224-330) domains of the heavy chain constant region as well as the hinge region (99-110) before the CH2 domain. The C103S version of the hIgG1 Fc protein is also available. The C103S substitution prevents improper cysteine bond formation in the absence of a light chain.

Molecular weight: Predicted 26.1 kDa. Due to glycosylation, the recombinant human IgG1 Fc protein migrates to 32-34 kDa based on the Bis-Tris PAGE result.
Purity: >95% by SDS-PAGE under reducing conditions
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.
Formulation: 0.2 μM filtered solution of 1x PBS.

Shipping: The in vivo grade recombinant human IgG1 Fc protein is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
1 month from date of receipt, 2 to 8°C as supplied.
3 months from date of receipt, -20°C to -70°C as supplied.

Background

The recombinant human IgG1 Fc protein (hIgG1 Fc) includes the CH2 and CH3 domains of the heavy chain constant region. Most of the therapeutic antibody drugs and Fc fusion proteins carry the natural human IgG1 Fc region or engineered mutants. The recombinant human IgG1 Fc protein can be used as the isotype control of the hIgG1 antibodies and the hIgG1 Fc fusion proteins in various in vitro and in vivo experiments.

Changes to the IgG Fc sequence including glycosylation sites have been used to modulate Fc functions. Even a single mutation may have both enhancement and abrogation effects of Fc binding. The following mutations have been introduced to alter the Fc region of an IgG1 antibody or an IgG1 Fc fusion protein to change its immunologic properties by Fc interaction with host proteins:

hIgG1 Fc R214K (Polatuzumab)
hIgG1 Fc R214K/N297A (Atezolizumab)
hIgG1 Fc L234A/L235A (Risankizumab)
hIgG1 Fc L234F/L235E/P331S (Durvalumab)
hIgG1 Fc L235A/G237A (Vedolizumab)
hIgG1 Fc D356E/L358M (Ocrelizumab)
hIgG1 Fc F126L (Necitumumab)
hIgG1 Fc D265A
hIgG1 Fc F243L/R292P/Y300L/V305I/P396L
hIgG1 Fc S239D/I332E
hIgG1 Fc S239D/I332E/A330L
hIgG1 Fc S298A/E333A/K334A
hIgG1 Fc G236A/S239D/I332E
hIgG1 Fc K326W/E333S
hIgG1 Fc S267E/H268F/S324T
hIgG1 Fc E345R/E430G/S440Y
hIgG1 Fc N297A
hIgG1 Fc N297Q
hIgG1 Fc N297G
hIgG1 Fc L235E
hIgG1 Fc L234A/L235A
hIgG1 Fc M252Y/S254T/T256E
hIgG1 Fc M428L/N434S
hIgG1 Fc S267E/L328F
hIgG1 Fc N325S/L328F

Recombinant natural and engineered human IgG1 Fc proteins, and recombinant human IgG1 isotype control antibody and mutants are available. Biotinylated hIgG1 Fc, and hIgG1 Fc with Avi-, His-, and Flag-tags are also available. Please contact us to ask for a quote for the engineered human IgG1 Fc proteins, biotinylated hIgG1 Fc, and hIgG1 Fc with Avi-, His-, and Flag-tags.